Member Portal    
ALS Trials
Browse Recruiting Trials
Search for a Trial
Clinical Trials 101
Questions about Clinical Research?
Contact an ALS Trial Liaison

Call or email us with your questions
about clinical research

(877) 458-0631

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) (BIO_ALS-01)

Study Focus:
The purpose of this study is to collect biofluid samples for the banking and usage in ALS research.
Amyotrophic Lateral Sclerosis (ALS), Sporadic ALS, Familial ALS, Primary Lateral Sclerosis (PLS), Hereditary Spastic Paraplegia (HSP), Healthy Volunteer, Other: Disease Mimics of ALS
Study Category:
Study Status:
Not Applicable
Observational Study
Funding Source:
Study Chair(s)/Principal Investigator(s):
Merit Cudkowicz, MD, MSc (Massachusetts General Hospital)
James D. Berry, MD, PhD (Massachusetts General Hospital)
Robert Bowser, PhD (Barrow Neurological Institute) ID:
Study ID:
NEALS Affiliated?
Study Summary:
The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression.

Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis. Studying components of the blood, such as DNA, may help us understand what happens when genes function abnormally and how it might be related to disease.
Participant Duration:
Up to 36 months
# of Subjects:
Enrollment Start Date:
Enrollment End Date:
Posting Last Modified Date:
Date Study Added to
More information:
Researchers tested what changes happen in volunteers with ALS that can be seen in the blood and what changes are unique to ALS and are different from those found in healthy volunteers and volunteers with neurological diseases other than ALS. These changes are called biomarkers. Biomarkers for ALS have been found in blood collected in earlier phases of this study. Biomarkers are non-genetic elements in your blood that may help to make diagnosing ALS easier. In the next phase, comparison of these changes in the blood of volunteers with ALS and without ALS will be used to confirm these biomarkers and to develop a tool to diagnose and monitor progression of ALS.
Eligibility Criteria
Male & Female
Minimum Age:
Maximum Age:
Min Vital Capacity (% predicted normal):
Time since Symptom Onset:
Less than 36 months
Can participants use Riluzole?
Coordinating Center
Contact Information
Daniela Grasso
NCRI at the Massachusetts General Hospital
149 13th Street, BLDG 149, MGH East
Boston, Massachusetts 02129
Other Eligibility Criteria:
Medically safe to have lumbar puncture

Site Contact Information

 (Please click to show/hide)
For Patients & Families
Educational Webinars
Online NEALS Resources
Other Resources
Contact a Disease Specialist
Clinical Research Blog

For Researchers
Become a NEALS member
Post an ALS Clinical Trial
NEALS CRO Capabilities
Annual NEALS Meeting
NEALS Samples
NEALS Historical Data
ALS Trials
Browse Recruiting Trials
Search for a Trial
Clinical Trial News
Clinical Trials 101

Get Involved
Donate samples
Donate to our Clinical Research
About Us
Our Mission
Our Structure
Our Research
NEALS Members
Motor Neuron Disease
Connect with us: Member Portal       Donate Now!       Help       Sitemap       Contact Us